

Essix Biosciences Limited

Regd. Off. : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh - 160101 (INDIA)
Phone : +91-172-2730503, 2730920, Fax : +91-172-2730504, 2736294
Place of Business: Village Bhabat, Zirakpur Ambala Highway, Zirakpur, Mohali- Punjab (India)
Ph. +91-9317812731, CIN NO. U74999CH1993PLC033428

Date: February 26, 2026

To,
The Listing Compliance Department
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051

To,
The Listing Compliance Department,
BSE Limited
P. J. Tower, Dalal Street
Mumbai – 400 001

Symbol: INDSWFTLAB

Scrip Code: 532305

**Subject : Disclosure under Regulation 29(2) of the Securities and Exchange Board of India
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011.**

Dear Sir/ Madam,

With reference to the captioned note that I, Himanshu Jain on behalf of Essix Biosciences Limited (“**Acquirer**”), members of Promoter & Promoter Group of Ind-Swift Laboratories Limited (“**Target Company**”) along with Nidhi Munjal, Meenakshi Mehta, Ravi Mehta, Neeta Munjal, Himanshu Jain, Sunita Jain, Gopal Munjal, Saurabh Munjal, Rishav Mehta, V.R. Mehta, Sahil Munjal, N.R. Munjal, S. R. Mehta, Bhanavi Mehta, Ishav Mehta, Deepti Munjal, Divya Munjal, Daksh Mehta, Annie Mehta (hereinafter collectively referred to as “**PACs**”), wish to inform your good office that the Acquirer, has acquired 51,00,000 (Fifty-One Lakh) Equity Shares of face value of Rs. 10/- each of the Target Company on Tuesday, February 24, 2026, pursuant to the conversion of Fully Convertible Warrants into Equity Shares.

In this regard, please find enclosed the disclosure under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 by Essix Biosciences Limited on behalf of the whole Promoter & Promoter group of the Company.

You are requested to take the same on records.

Thanking You.

Yours Faithfully,


For ESSIX BIOSCIENCES LIMITED


HIMANSHU JAIN
DIRECTOR

DIN: 00014533

Date: February 26, 2026

Place: Chandigarh



CC:

The Board of Directors

Ind- Swift Laboratories Limited

SCO:850, Shivalik Enclave, NAC, Manimajra, Chandigarh-160101, India

Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers)

Regulations, 2011

Name of the Target Company (TC)	Ind- Swift Laboratories Limited		
Names of the Acquirer and Persons Acting in Concert (PAC) with the Acquirer	Essix Biosciences Limited ("Acquirer") 1. Nidhi Munjal, 2. Meenakshi Mehta, 3. Ravi Mehta, 4. Neeta Munjal, 5. Himanshu Jain, 6. Sunita Jain, 7. Gopal Munjal, 8. Saurabh Munjal, 9. Rishav Mehta, 10. V.R. Mehta, 11. Sahil Munjal, 12. N.R. Munjal, 13. S. R. Mehta, 14. Bhanavi Mehta, 15. Ishav Mehta, 16. Deepti Munjal, 17. Divya Munjal, 18. Daksh Mehta, 19. Annie Mehta (Collectively referred to as "PACs")		
Whether the Acquirer belongs to Promoter/Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	1. National Stock Exchange of India Limited (" NSE ") and 2. BSE Limited (" BSE ")		
Details of the acquisition as follows	Number	% w.r.t. total Share/voting capital wherever applicable	% w.r.t. total diluted Share/voting capital of the TC
Before the acquisition/disposal under consideration, holding of:			
a. Shares carrying voting rights:			
Acquirer:			
<i>Essix Biosciences Limited</i>	2,77,82,521	34.04	29.81*
<i>PAC's</i>	44,51,757	5.45	4.78*



b. Shares in the nature of encumbrance (pledge/ lien/non-disposal undertaking/ others)	Nil	NA	NA
c. Voting rights (VR) otherwise than by equity shares	Nil	NA	NA
d. Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category):	Nil	NA	NA
Acquirer: <i>Essix Biosciences Limited</i>	51,00,000	-	5.47*
e. Total (a+b+c+d)	3,73,34,278	39.50	40.05
Details of acquisition			
a. Shares carrying voting rights acquired/sold:-			
Acquirer:			
<i>Essix Biosciences Limited</i>	51,00,000	5.88	5.47
b. VRs acquired /sold otherwise than by shares	Nil	NA	NA
c. Warrants/ convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold:	Nil	NA	NA
d. Shares encumbered/invoked/released by the acquirer	Nil	NA	NA
e. Total (a+b+c+d)	51,00,000	5.88	5.47
After the acquisition, holding of:			
a. Shares carrying voting rights:			
Acquirer:			
<i>Essix Biosciences Limited</i>	3,28,82,521	37.92	35.28
<i>PACs</i>	44,51,757	5.13	4.78
b. Shares encumbered with the acquirer	Nil	NA	NA
c. VRs otherwise than by equity shares	Nil	NA	NA
d. Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition:			
e. Total (a+b+c+d)	3,73,34,278	43.06	40.05
Mode of acquisition (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter se transfer etc.)	Preferential Allotment (Equity Shares allotted pursuant to the conversion of Fully Convertible Warrants)		



Date of receipt of intimation of allotment of shares, whichever is applicable	February 24, 2026 ("Date of Allotment")
Equity share capital / total voting capital of the TC before the said acquisition	Rs. 81,61,15,580/- divided into 8,16,11,558 Equity Shares of face value of Rs. 10/- each.
Equity share capital/ total voting capital of the TC after the said acquisition	Rs. 86,71,15,580/- divided into 8,67,11,558 Equity Shares of face value of Rs. 10/- each.
Total diluted share/voting capital of the TC after the said acquisition	Rs. 93,21,15,580/- divided into 9,32,11,558 Equity Shares of face value of Rs. 10/- each.

**Percentages have been calculated at Fully Diluted Pre Capital of 9,32,11,558 Securities including 8,16,11,558 Equity Shares, and 1,16,00,000 Fully Convertible Warrants.*

For Essix Biosciences Limited

HIMANSHU JAIN
DIRECTOR

DIN: 00014533

Date: February 26, 2026

Place: Chandigarh

